Nicotinamide Mononucleotide (NMN)
What it is
Nicotinamide mononucleotide (NMN) is a nucleotide — specifically a ribonucleotide — that functions as a direct precursor to nicotinamide adenine dinucleotide (NAD+), one of the most important coenzymes in human biology. NAD+ participates in hundreds of enzymatic reactions spanning energy metabolism, DNA repair, gene expression regulation, and the activity of sirtuins, a family of enzymes with roles in cellular stress responses. Only the beta isomer of NMN is biologically active; commercial products should contain beta-NMN specifically.
NAD+ levels in human tissues decline with age — estimates suggest a reduction of around 40–50% between young adulthood and later life, though the rate and tissue specificity of this decline varies considerably between individuals. This age-related fall has generated substantial interest in whether supplementing NAD+ precursors could offset some of the physiological changes associated with ageing. NMN sits close to NAD+ in the biosynthetic pathway — one step away — which has led to claims that it represents a particularly direct or efficient route to raising cellular NAD+.
After oral ingestion, NMN is absorbed in the small intestine, with some evidence for a dedicated intestinal transporter (Slc12a8) facilitating uptake. Once absorbed, NMN enters the NAD+ salvage pathway and can be detected in blood within minutes of ingestion. There is ongoing mechanistic debate about whether circulating NMN is taken up directly into cells or whether it must first be converted to nicotinamide riboside (NR) before entering cells via equilibrative nucleoside transporters. This question has practical implications for understanding how efficiently oral NMN translates into intracellular NAD+ elevation across different tissues — a distinction that remains incompletely resolved in human studies.
NMN is found naturally in small amounts in some foods including edamame, broccoli, cucumber, and beef, though dietary quantities are insufficient to meaningfully raise systemic NAD+ levels. As a supplement, it is commercially available as an oral capsule or powder, typically at doses of 250–500 mg per day, with research doses ranging from 125 mg to 2000 mg/day.
What the evidence shows
Blood NAD+ elevation
The most consistently reported effect of oral NMN supplementation in humans is an increase in blood NAD+ levels, with findings generally consistent across trials, though not all have reached statistical significance and measurement methods vary. A majority of trials within published meta-analyses have documented increases in whole blood or peripheral blood mononuclear cell (PBMC) NAD+ following supplementation. This biomarker response is real, reproducible, and dose-related — trials have recorded substantial increases in whole blood NAD+ levels (in some cohorts, often in the range of approximately 1.5–2.5-fold above placebo), with higher doses generally producing larger responses. Individual responses are highly variable, influenced by baseline NAD+ status, age, sex, and likely gut microbiome composition.
Raising blood NAD+ is not the same as raising intracellular NAD+ across relevant tissues such as muscle, liver, or brain. Blood is a convenient measurement compartment but does not necessarily reflect what is happening in the tissues where age-related NAD+ decline is most clinically significant. This limitation runs through the entire human evidence base for NMN and should be held clearly in mind when interpreting biomarker results.
Physical function
A moderate signal for improved physical performance exists in older adults. A 12-week double-blind RCT in adults aged 65–75 years found that 250 mg/day NMN significantly reduced 4-metre walking time compared with placebo, alongside increases in blood NAD+ and its metabolites. A separate multicenter RCT found dose-dependent improvements in walking distance at doses of 300, 600, and 900 mg/day. A 2024 meta-analysis pooling data from nine studies (412 participants) reported a statistically significant effect on gait speed (standardised mean difference 0.34, 95% CI 0.03–0.66). This is an encouraging pattern but it comes with important qualifications: the trials are small, some involve specific clinical populations (older adults with diabetes and impaired physical performance), and the effect sizes are modest. Whether these gait improvements translate to reduced fall risk, sustained functional independence, or any hard clinical endpoint has not been tested.
Metabolic outcomes
Two independent 2024 meta-analyses examined the effects of NMN on markers of glucose and lipid metabolism. Both reached consistent conclusions: pooled analyses found no significant benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR, total cholesterol, LDL-C, HDL-C, or triglycerides. One borderline signal for HOMA-IR (p=0.06, based on three trials) disappeared after excluding a trial where the apparent improvement in the NMN group was driven by deterioration in the placebo group rather than active improvement. One of these meta-analyses noted explicitly that a risk of overestimation of NMN's benefits may exist in the published field, given that high risk of bias was found in approximately half of included trials. The metabolic evidence, as currently constituted, does not support a clinically meaningful effect of NMN supplementation on glucose or lipid metabolism in generally healthy adults.
Cardiovascular and vascular markers
A small number of trials have examined arterial stiffness, blood pressure, and lipid markers. A 12-week RCT in 36 healthy middle-aged adults using 250 mg/day reported significant reductions in diastolic blood pressure, LDL cholesterol, and a measure of arterial stiffness. A 28-day trial using a higher-dose proprietary formulation (MIB-626, 1000 mg/day) found reductions in LDL, total cholesterol, and body weight, and a significant decrease in diastolic blood pressure in participants with above-mean baseline blood glucose. These are unreplicated signals from underpowered, industry-linked trials and should not be interpreted as reliable findings pending independent replication.
Cognitive and neurological outcomes
No adequately powered RCT has examined cognitive outcomes as a primary endpoint in humans. Animal model data exists suggesting NAD+ restoration has effects on neurodegeneration models, but the translation of these findings to human clinical benefit has not been tested. Clinically, this area should be regarded as preclinical hypothesis-generating only.
The five questions
Does low status cause harm that supplementation corrects?
NMN is not an essential nutrient in the traditional deficiency sense — there is no clinically defined NMN deficiency state and no established lower threshold below which health is demonstrably impaired in the way that applies to, for example, iron or vitamin D. However, NAD+ levels do decline with age, and this decline is associated with impaired cellular function in animal models. Whether this age-related reduction is a cause of functional decline or simply a correlate — and whether supplementation corrects it in a clinically meaningful way — has not been established in humans. The framing of NMN as correcting a nutritional deficiency is not supported by current evidence.
Does supplementation prevent disease in at-risk populations?
There is no human evidence that NMN supplementation prevents any disease in at-risk populations. Animal model data, including mouse studies showing improvements in metabolic disease, cardiovascular function, and neurodegeneration models, is extensive and internally consistent in several domains — but animal-to-human translation in ageing biology has repeatedly proven unreliable. No human trial has been powered or designed to test disease incidence as a primary endpoint.
Does NMN produce meaningful biomarker effects?
Yes, in a specific and narrow sense. Oral NMN reliably raises blood NAD+ levels in middle-aged and older adults. This is the most robust finding in the human literature. The magnitude is dose-dependent and individually variable. The clinical significance of this biomarker change — whether it translates to the cellular outcomes measured in animal models — is not established. Beyond NAD+ elevation, the evidence for clinically meaningful biomarker effects (metabolic markers, inflammatory markers, body composition) is weak and inconsistent across trials.
Does NMN improve outcomes in clinical populations?
There is limited early-stage evidence in specific clinical populations. Trials in older adults with diabetes and impaired physical performance, and in middle-aged adults with metabolic risk factors, have produced some signals for improved gait speed and modest cardiovascular marker changes. These signals are insufficient to support clinical use given the trial sizes, bias risks, and absence of replication. NMN is not approved or recommended as a treatment for any clinical condition.
Does NMN benefit healthy, replete adults?
This is where the gap between commercial positioning and evidence is widest. Most of the supplementation market for NMN targets generally healthy adults without documented NAD+ decline, impaired physical function, or metabolic disease. The published trial populations are predominantly middle-aged to older adults (40–75 years), often with at least some age-related functional decline as the basis for inclusion. Whether NMN produces any measurable or clinically meaningful benefit in genuinely healthy younger adults has not been studied. There is a reasonable biological rationale for studying NMN as a preventive or health-maintenance intervention in ageing populations, but rationale is not evidence.
Individual variation
Response to NMN supplementation is substantially variable between individuals. Baseline NAD+ levels — which decline with age and vary by sex, ethnicity, lifestyle (exercise raises NAD+), and diet — appear to be a key moderator of response: participants with lower starting NAD+ levels show larger absolute increases and may show greater functional responses. A post-hoc analysis of the Yi et al. 2023 multicenter RCT found that the low-dose group did not show overall improvements in walking tests, likely because large variation in baseline NAD+ levels obscured any signal; a correlation between NAD+ change and improved walking performance was identified only in post-hoc analysis.
Gut microbiome composition also modulates NMN metabolism. Some gut bacteria can degrade NMN before absorption, reducing systemic availability. Genetic variation in enzymes of the NAD+ salvage pathway (including NAMPT, NMNATs, and CD38) likely contributes to variation in both the biomarker and functional response, but systematic characterisation of pharmacogenomic predictors does not yet exist in the human literature.
Sex may be a meaningful moderator. A 2024 preprint mouse study reported that NMN extended median lifespan by 8.5% in female but not male mice, with sex-specific effects on NAD+ metabolism. The relevance to human biology is unknown.
Testing and status assessment
There is no standardised clinical test for NAD+ status in current routine practice. Research methods include whole blood NAD+ measurement and PBMC NAD+ assay, but reference ranges, between-lab standardisation, and the relationship between blood NAD+ and tissue NAD+ in relevant organs are poorly defined. Some private laboratories offer NAD+ testing but the clinical interpretation of results — including what constitutes a level warranting supplementation — has no evidence-based consensus. Blood NAD+ testing can confirm that supplementation is raising levels in the circulation, but cannot confirm that target tissues are responding or that the response is clinically meaningful.
Safety
Short-term oral NMN supplementation appears to be well tolerated across published trials. Studies using doses up to 1250 mg/day for periods of up to 12 weeks have not identified clinically significant adverse effects on liver enzymes, kidney function, haematological markers, or cardiovascular parameters. Mild gastrointestinal symptoms including nausea and loose stools have been reported at higher doses. Human long-term safety data (beyond 12 weeks) is limited.
The question of whether raising NAD+ could fuel pre-existing tumour growth is scientifically plausible — cancer cells upregulate NAD+ salvage enzymes (notably NAMPT) and are metabolically dependent on NAD+. However, no clinical data demonstrate that NMN supplementation increases cancer risk in healthy individuals. A 2024 mouse lifespan study found no increase in tumour burden with chronic NMN use, and a separate mouse model of colitis-associated colorectal cancer found fewer tumours in NMN-supplemented animals. The current evidence does not support a causal link between NMN supplementation and cancer promotion in healthy individuals, but caution is appropriate for people with active malignancy, and anyone on cancer treatment should seek medical guidance before taking NMN.
Intravenous NAD+ infusions are offered commercially in wellness clinics and, increasingly, by private medical practitioners as an anti-ageing or recovery intervention. This deserves explicit comment. IV NAD+ is not NMN, not a studied oral supplement form, and not underpinned by a meaningful clinical evidence base. NAD+ administered intravenously is unable to cross cell membranes intact — it is rapidly hydrolysed in the extracellular environment into NMN and then NR, which are then taken up by cells. The route of administration results in large acute increases in circulating NAD+ metabolites including nicotinamide and ADP-ribose, the clinical consequences of which are poorly characterised. Published pilot data on IV NAD+ tolerability document dose-dependent adverse experiences during infusion including nausea, headache, diarrhoea, and muscle tightness, typically requiring slow infusion rates of several hours to minimise symptoms. No controlled trial has demonstrated clinical benefit from IV NAD+ infusions in healthy adults. The commercial practice of offering IV NAD+ as a longevity or wellness intervention is substantially ahead of the evidence and warrants scepticism.
NMN has not been studied in pregnancy or breastfeeding. Supplementation during these periods should be avoided in the absence of safety data.
What can reasonably be concluded
NMN is a biologically credible intervention for raising blood NAD+ levels in ageing adults, and this biomarker effect is reproducibly demonstrated in human trials. The commercial and clinical excitement around NMN — including its use in IV form — has, however, substantially outpaced what the human evidence actually shows. No clinical outcome relevant to healthy ageing, disease prevention, or meaningful functional improvement has been convincingly demonstrated in adequately powered, independently replicated human trials. Two independent 2024 meta-analyses found no significant benefit on metabolic markers. Signals in physical function and cardiovascular markers exist but come from small, industry-connected trials with material risk of bias.
The comparison between NMN and the preclinical animal literature is worth making explicitly: mouse models have produced large effects — improved metabolism, reduced frailty, increased lifespan — but ageing biology is notoriously species-specific, and interventions that extend healthspan in rodents have a poor record of translating to humans. Whether the NAD+ biomarker effect achievable with oral NMN is sufficient to reproduce any of these animal model benefits in human tissues, over meaningful timescales, is genuinely unknown.
There is no established basis for the commercial practice of IV NAD+ infusions in healthy adults. The mechanistic rationale is weak, the clinical evidence base is minimal, tolerability is variable and often poor during infusion, and the cost to benefit ratio is unjustified by the available data.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.